We create minimally invasive medical technology addressing patient needs from diagnosis to therapy.

“We Think Big by Creating Small”


April 11 – 15, 2018:  TransMed7, LLC highlighted its SpeedBird, Concorde, and Cardinal technologies at the Annual Meeting of the Society of Breast Imaging in Las Vegas

Attending the annual meeting of the Society of Breast Imaging (SBI) in Las Vegas on behalf of TransMed7 were James W. Vetter, TransMed7 Co-Founder and Chairman, Dr. Edgar D. Staren, TransMed7 President and Executive Chair of its Clinical and Scientific Advisory Board (CSAB) and its Business Advisory Board, and Beth Boyd, TransMed7 Clinical Coordinator.  Also attending were Dr. Richard E. Fine, Director of Education and Research at the Margaret West Comprehensive Breast Center, Associate Professor of Surgery at the University of Tennessee College of Medicine, and Chair of TransMed7’s Breast Health Team and Executive Committee member of its CSAB as well as Dr. Jocelyn Rapelyea, Professor of Radiology, George Washington School of Medicine and TransMed7 CSAB Breast Health Team member. Mr. Greg Carpenter was also in attendance at the meeting; Mr. Carpenter will be officially joining as National Sales Manager for Concorde MD, LLC, a subsidiary of TransMed7 and responsible for development of its Concorde stereotactic and 2D/3D Tomosynthesis guided biopsy device platform, on May 1, 2018.  The meeting participants were primarily composed of radiologists who are dedicated to the practice of breast imaging and image-guided intervention. These clinicians were introduced to TransMed7 and its innovative portfolio of minimal access medical devices. In addition to engaging with the TransMed7 team at its booth, a number of key opinion leaders (KOLs) attending the meeting were invited to participate in a separate, hands-on, image-guided demonstration of the devices. Comments from these KOLs included: “it was very easy to visualize the rotating needle tip on ultrasound’…”the device was easy to use”…and, “the samples were large and of high quality”.  We are pleased with the results of this important event and the related progress introducing TransMed7 and its products to this distinguished group of clinicians.  These results move us further down the path of meeting our mission to efficiently design, develop, and deliver transformational, minimal access medical devices which address patient needs from diagnosis to therapy.


Further Company Information